OBI Pharma, Inc. (4174.TWO)
TWD 51.2
(-8.24%)
TWD 51.2
(-8.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.04 Billion TWD | 33.35% |
| 2022 | -1.89 Billion TWD | -10.56% |
| 2021 | -1.71 Billion TWD | -15.3% |
| 2020 | -1.48 Billion TWD | -3.49% |
| 2019 | -1.43 Billion TWD | -17.78% |
| 2018 | -1.22 Billion TWD | 11.4% |
| 2017 | -1.37 Billion TWD | -24.26% |
| 2016 | -1.11 Billion TWD | -17.93% |
| 2015 | -941.33 Million TWD | -41.13% |
| 2014 | -667 Million TWD | -52.08% |
| 2013 | -438.58 Million TWD | -71.81% |
| 2012 | -255.27 Million TWD | -100.08% |
| 2011 | -127.58 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -540.66 Million TWD | -3.52% |
| 2024 Q1 | -522.25 Million TWD | 7.71% |
| 2024 Q3 | -561.79 Million TWD | 3.95% |
| 2023 Q3 | -567.83 Million TWD | -238.84% |
| 2023 Q4 | -565.91 Million TWD | 0.34% |
| 2023 FY | -1.26 Billion TWD | 33.35% |
| 2023 Q1 | -421.8 Million TWD | 35.98% |
| 2023 Q2 | 408.98 Million TWD | 196.96% |
| 2022 FY | -1.89 Billion TWD | -10.56% |
| 2022 Q3 | -453.34 Million TWD | -10.03% |
| 2022 Q1 | -375.14 Million TWD | 32.86% |
| 2022 Q2 | -412.01 Million TWD | -9.83% |
| 2022 Q4 | -658.82 Million TWD | -45.32% |
| 2021 Q4 | -558.72 Million TWD | -71.98% |
| 2021 FY | -1.71 Billion TWD | -15.3% |
| 2021 Q2 | -415.79 Million TWD | -79.77% |
| 2021 Q3 | -324.87 Million TWD | 21.87% |
| 2021 Q1 | -231.29 Million TWD | 37.33% |
| 2020 Q1 | -313.88 Million TWD | 38.51% |
| 2020 Q3 | -380.46 Million TWD | -20.96% |
| 2020 Q2 | -314.52 Million TWD | -0.2% |
| 2020 FY | -1.48 Billion TWD | -3.49% |
| 2020 Q4 | -369.07 Million TWD | 2.99% |
| 2019 Q2 | -362.45 Million TWD | -70.01% |
| 2019 FY | -1.43 Billion TWD | -17.78% |
| 2019 Q1 | -213.19 Million TWD | 47.24% |
| 2019 Q3 | -320.92 Million TWD | 11.46% |
| 2019 Q4 | -510.45 Million TWD | -59.06% |
| 2018 Q3 | -415.18 Million TWD | -195.62% |
| 2018 Q1 | -262.56 Million TWD | 26.79% |
| 2018 FY | -1.22 Billion TWD | 11.4% |
| 2018 Q4 | -404.05 Million TWD | 2.68% |
| 2018 Q2 | -140.44 Million TWD | 46.51% |
| 2017 FY | -1.37 Billion TWD | -24.26% |
| 2017 Q4 | -358.65 Million TWD | -6.52% |
| 2017 Q3 | -336.7 Million TWD | -20.28% |
| 2017 Q2 | -279.94 Million TWD | 30.73% |
| 2017 Q1 | -404.12 Million TWD | -45.61% |
| 2016 FY | -1.11 Billion TWD | -17.93% |
| 2016 Q1 | -348.08 Million TWD | -33.69% |
| 2016 Q4 | -277.53 Million TWD | 24.47% |
| 2016 Q2 | -117.09 Million TWD | 66.36% |
| 2016 Q3 | -367.42 Million TWD | -213.79% |
| 2015 Q2 | -173.18 Million TWD | 53.61% |
| 2015 FY | -941.33 Million TWD | -41.13% |
| 2015 Q4 | -260.36 Million TWD | -93.67% |
| 2015 Q3 | -134.44 Million TWD | 22.37% |
| 2015 Q1 | -373.34 Million TWD | -100.04% |
| 2014 Q3 | -151.65 Million TWD | 28.81% |
| 2014 Q2 | -213.02 Million TWD | -84.13% |
| 2014 Q1 | -115.69 Million TWD | 15.42% |
| 2014 FY | -667 Million TWD | -52.08% |
| 2014 Q4 | -186.63 Million TWD | -23.07% |
| 2013 Q1 | -101.23 Million TWD | -31.26% |
| 2013 Q2 | -154.13 Million TWD | -52.26% |
| 2013 FY | -438.58 Million TWD | -71.81% |
| 2013 Q3 | -99.33 Million TWD | 35.55% |
| 2013 Q4 | -136.78 Million TWD | -37.7% |
| 2012 Q4 | -77.12 Million TWD | 0.0% |
| 2012 Q3 | -77.12 Million TWD | 0.0% |
| 2012 FY | -255.27 Million TWD | -100.08% |
| 2011 FY | -127.58 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| SYN-TECH Chem. & Pharm. Co., Ltd. | 251.01 Million TWD | 516.901% |
| Level Biotechnology Inc. | 62.9 Million TWD | 1763.58% |
| Sagittarius Life Science Corp | -55.03 Million TWD | -1801.334% |
| NeoCore Technology Co., Ltd. | -64.64 Million TWD | -1518.803% |
| TaiMed Biologics Inc. | -194.81 Million TWD | -437.177% |
| GlycoNex Incorporation | -178.36 Million TWD | -486.714% |
| VBI | -6.6 Million TWD | -15753.28% |
| GeneReach Biotechnology Corp. | -166.27 Million TWD | -529.383% |
| Taiwan Advance Bio-Pharmaceutical Inc. | -10.68 Million TWD | -9696.62% |
| Visgeneer Inc. | -19.58 Million TWD | -5242.156% |
| Mycenax Biotech Inc. | -682.84 Million TWD | -53.252% |
| Sunmax Biotechnology Co., Ltd. | 625.7 Million TWD | 267.247% |
| G&E Herbal Biotechnology Co., Ltd. | 72.4 Million TWD | 1545.407% |
| Medigen Vaccine Biologics Corporation | -1.15 Billion TWD | 9.774% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -6.04 Million TWD | -17205.689% |
| Enimmune corporation | -223.74 Million TWD | -367.713% |
| TaiRx, Inc. | -212.29 Million TWD | -392.941% |
| CHO Pharma, Inc. | -306.08 Million TWD | -241.888% |
| EirGenix Inc. | -915.2 Million TWD | -14.343% |
| BioLASCO Taiwan Co., Ltd. | 49.74 Million TWD | 2203.763% |
| Sunny Pharmtech Inc. | -63.32 Million TWD | -1552.677% |
| Lin BioScience, Inc. | -687.19 Million TWD | -52.283% |
| BioGend Therapeutics Co., Ltd. | -156.32 Million TWD | -569.423% |
| Feng Chi Biotech Corp. | 22.79 Million TWD | 4691.414% |
| Bio Preventive Medicine Corp. | -73.28 Million TWD | -1327.953% |
| Lukas Biomedical Inc. | -47.35 Million TWD | -2109.944% |
| RBC Bioscience Corporation | 6.43 Million TWD | 16374.883% |
| BiOptic Inc. | 37.74 Million TWD | 2872.34% |
| BRIM Biotechnology, Inc. | -688.02 Million TWD | -52.099% |
| Shine-On BioMedical Co.,Ltd. | -37.16 Million TWD | -2715.754% |
| Great Novel Therapeutics Biotech & Medicals | -61.54 Million TWD | -1600.479% |
| Syngen Biotech Co.,Ltd. | 274.82 Million TWD | 480.776% |
| Anti-Microbial Savior BioteQ Co., Ltd | -51.78 Million TWD | -1920.924% |
| SynCore Biotechnology Co.,Ltd | -38.17 Million TWD | -2641.473% |
| Genomics BioSci & Tech. Co.,Ltd. | -168.06 Million TWD | -522.657% |
| Neith Corporation | -40.03 Million TWD | -2514.031% |
| Advagene Biopharma Co., Ltd. | -92.11 Million TWD | -1036.114% |
| NaviFUS Corp. | -65.72 Million TWD | -1492.105% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -88.08 Million TWD | -1087.975% |
| Sinew Pharma Inc. | -170.92 Million TWD | -512.257% |
| Andros Pharmaceuticals Co.,Ltd | -68.15 Million TWD | -1435.344% |
| Greenyn Biotechnology Co., Ltd | 130.66 Million TWD | 900.89% |
| Lumosa Therapeutics Co., Ltd. | -238.04 Million TWD | -339.62% |
| AP Biosciences Inc | -339.29 Million TWD | -208.426% |
| Medigen Biotechnology Corp. | -561.29 Million TWD | -86.439% |
| 3D Global Biotech Inc. | -57.95 Million TWD | -1705.793% |
| Pharmosa Biopharm Inc. | 8.45 Million TWD | 12475.532% |
| Intech Biopharm Corporation | -337.98 Million TWD | -209.62% |
| Oneness Biotech Co., Ltd. | -1.31 Billion TWD | 20.291% |
| Eusol Biotech Co.,Ltd. | -51.61 Million TWD | -1927.542% |
| TWi Biotechnology, Inc. | -170.68 Million TWD | -513.11% |
| Ever Supreme Bio Technology Co., Ltd | 539.39 Million TWD | 294.008% |
| TCI GENE Inc. | 11.67 Million TWD | 9064.919% |
| MegaPro Biomedical Co., Ltd | -127.54 Million TWD | -720.456% |
| Senhwa Biosciences, Inc. | -296.3 Million TWD | -253.174% |
| Taiwan Bio Therapeutics Co., Ltd | -217.51 Million TWD | -381.111% |
| NatureWise Biotech & Medicals Corporation | 10.12 Million TWD | 10440.662% |
| PharmaEngine, Inc. | 274.65 Million TWD | 481.021% |
| Savior Lifetec Corporation | 30.03 Million TWD | 3584.765% |
| TaiGen Biopharmaceuticals Holdings Limited | 136.73 Million TWD | 865.353% |
| Meribank Biotech Co., Ltd | -125.34 Million TWD | -734.869% |
| Acepodia, Inc. | -817.31 Million TWD | -28.038% |
| Caliway Biopharmaceuticals Co., Ltd. | -488.45 Million TWD | -114.242% |